Analyst Phil Nadeau from TD Cowen maintained a Buy rating on Dynavax (DVAX – Research Report) and keeping the price target at $25.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Phil Nadeau’s rating is based on Dynavax’s solid performance and future growth potential. The company reported consistent Heplisav sales for Q4, aligning with previous forecasts, and achieved a significant year-over-year increase. Looking forward, Dynavax anticipates an increase in Heplisav revenue and expects to capture a majority share of the growing U.S. adult hepatitis B vaccine market by 2027.
Furthermore, Dynavax’s strong cash position and ongoing clinical trials, such as the Phase I/II study for the Z-1018 shingles vaccine, highlight its potential for future development and market expansion. These factors contribute to the perception that the company’s stock is undervalued, prompting a Buy rating from Nadeau.
Nadeau covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Neurocrine, and Dynavax. According to TipRanks, Nadeau has an average return of 2.7% and a 41.61% success rate on recommended stocks.